Nimrat Bains, PA
Physician Assistant · Belpre, OHNPI 1093285629
Payments from drug & device makers
Across 72 payments — averaging $34.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$431
- Insulet Corporation$323
- Sanofi-aventis U.S. LLC$139
- Lilly USA, LLC$82
- AstraZeneca$76
- plus $420 from 16 others
What the payments were for
- Travel & lodging$59224%
- Food & beverage$1,90676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $1,027 |
| Novo Nordisk | 16 | $431 |
| Insulet Corporation | 10 | $323 |
| Sanofi-aventis U.S. LLC | 3 | $139 |
| Lilly USA, LLC | 5 | $82 |
| AstraZeneca(2 entities) | 5 | $76 |
| Dexcom, Inc. | 2 | $55 |
| Boehringer Ingelheim | 3 | $43 |
| Corcept Therapeutics | 2 | $41 |
| Amgen | 2 | $36 |
| Radius Health, Inc. | 2 | $32 |
| Cequr Corporation | 1 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| BD | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Abbott | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$741
- Wegovy$115
How this compares
$2,498 in reported general payments places this provider in the 85th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 527 | $590,684 |
| OzempicSemaglutide | 506 | $541,884 |
| TrulicityDulaglutide | 396 | $409,548 |
| JardianceEmpagliflozin | 402 | $349,438 |
| FarxigaDapagliflozin Propanediol | 178 | $152,072 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 77 | $142,165 |
| Tresiba Flextouch U-200Insulin Degludec | 166 | $137,450 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $68,331 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $67,971 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 134 | $66,517 |
| Novolog FlexpenInsulin Aspart | 198 | $55,573 |
| Humalog Kwikpen U-100Insulin Lispro | 160 | $54,586 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $54,025 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 372 | $52,614 |
| RybelsusSemaglutide | 27 | $44,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $82 | $1,000,231923 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $431 | $608,633590 claims |
| Boehringer IngelheimJardiance, Tradjenta | $43 | $362,089415 claims |
| AstraZenecaFarxiga | $76 | $152,072178 claims |
| AmgenProlia | $36 | $43,78426 claims |
| Cequr CorporationCequr Simplicity | $30 | $16,13130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Belpre
- Erin StrculaBelpre$106K
- Nathan MiselBelpre$19K
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.